GTHX G1 Therapeutics Inc

USD 4.47 0.18 4.195804
Icon

G1 Therapeutics Inc (GTHX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 4.47

+0.18 (+4.20)%

USD 0.21B

1.61M

USD 8.00(+78.97%)

USD 11.00 (+146.09%)

Icon

GTHX

G1 Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 4.47
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.21B

USD 11.00 (+146.09%)

USD 4.47

G1 Therapeutics Inc (GTHX) Stock Forecast

Show ratings and price targets of :
USD 8.00
(+78.97%)

Based on the G1 Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for G1 Therapeutics Inc is USD 8.00 over the next 12 months. G1 Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of G1 Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, G1 Therapeutics Inc’s stock price was USD 4.47. G1 Therapeutics Inc’s stock price has changed by +29.57% over the past week, +86.25% over the past month and +60.22% over the last year.

No recent analyst target price found for G1 Therapeutics Inc
No recent average analyst rating found for G1 Therapeutics Inc

Company Overview G1 Therapeutics Inc

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease inci...Read More

700 Park Offices Drive, Research Triangle Park, NC, United States, 27709

100

December

USD

USA

Adjusted Closing Price for G1 Therapeutics Inc (GTHX)

Loading...

Unadjusted Closing Price for G1 Therapeutics Inc (GTHX)

Loading...

Share Trading Volume for G1 Therapeutics Inc Shares

Loading...

Compare Performance of G1 Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for GTHX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To G1 Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -1.14 (-0.27%) USD107.38B 29.93 21.06

ETFs Containing GTHX

Symbol Name GTHX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About G1 Therapeutics Inc (GTHX) Stock

Based on ratings from 3 analysts G1 Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, 1 sell and hold ratings.

Unfortunately we do not have enough data on GTHX's stock to indicate if its a good dividend stock.

Based on targets from 3 analysts, the average taret price for GTHX is USD 8.00 over the next 12 months. The maximum analyst target price is USD 14 while the minimum anlayst target price is USD 4.

Unfortunately we do not have enough data on GTHX's stock to indicate if its overvalued.

The last closing price of GTHX's stock was USD 4.47.

The most recent market capitalization for GTHX is USD 0.21B.

Based on targets from 3 analysts, the average taret price for GTHX is projected at USD 8.00 over the next 12 months. This means that GTHX's stock price may go up by +78.97% over the next 12 months.

We can't find any ETFs which contains G1 Therapeutics Inc's stock.

As per our most recent records G1 Therapeutics Inc has 100 Employees.

G1 Therapeutics Inc's registered address is 700 Park Offices Drive, Research Triangle Park, NC, United States, 27709. You can get more information about it from G1 Therapeutics Inc's website at https://www.g1therapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...